The Claim
In overweight or obese adults with type 2 diabetes inadequately controlled on metformin or metformin plus sulfonylurea, 14 weeks of liraglutide treatment at up to 1.8 mg/day is associated with a reduction in HbA1c by 0.9%, BMI by 1.4 kg/m², and total body fat mass by 0.5%.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In overweight or obese adults with type 2 diabetes not fully controlled by metformin or metformin plus sulfonylurea, 14 weeks of liraglutide at up to 1.8 mg per day reduces HbA1c by 0.9%, BMI by 1.4 kg/m², and total body fat mass by 0.5%.
See the scientific wording
In overweight or obese adults with type 2 diabetes inadequately controlled on metformin or metformin plus sulfonylurea, 14 weeks of liraglutide treatment at up to 1.8 mg/day is associated with a reduction in HbA1c by 0.9%, BMI by 1.4 kg/m², and total body fat mass by 0.5%, suggesting a potential role in improving metabolic parameters in this population.
Liraglutide activates receptors in the pancreas and brain that make the body use insulin better, stop making too much sugar in the liver, burn fat for energy, and eat less food, which lowers blood sugar and reduces body fat.
What the research says
1 studyThis study found that obese adults with type 2 diabetes who took liraglutide for 14 weeks had lower blood sugar, lost a little weight, and lost a small amount of body fat — exactly what the claim says. It’s like the medicine helped their body work better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.